Skip to main content
Top
Published in: Medical Oncology 2/2015

01-02-2015 | Original Paper

Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway

Authors: Cuixia Yang, Linyan He, Pingqing He, Yiwen Liu, Wenjuan Wang, Yiqing He, Yan Du, Feng Gao

Published in: Medical Oncology | Issue 2/2015

Login to get access

Abstract

Tumor-associated macrophages (TAMs) appear to be the major component in solid tumor microenvironment, which were reported to play an important role in tumor malignant progression. Recently, TAMs were reported to be associated with drug resistance in some types of solid tumor including breast cancer. However, how TAMs regulate breast tumor resistance remains unknown. In this study, THP-1 cells were stimulated with PMA and IL-4/IL-13 to form M2-like macrophages to study the role of TAMs on chemoresistance. Our results showed that TAMs and its supernatants significantly prevent breast tumor cells from apoptosis caused by paclitaxel. We also found that the high level of IL-10 secreted by TAMS was responsible for drug resistance of breast cancer. The possible TAMs-modulated drug resistance mechanism involved may be associated with elevation of bcl-2 gene expression and up-regulation of STAT3 signaling in tumor cells. Furthermore, the blockage of TAMs-derived IL-10 by neutralizing antibody resulted in attenuation of STAT3 activation and decrease of bcl-2 mRNA expression, consequently enhanced sensitivity of breast cancer cells. Our data suggested that TAMs might induce drug resistance through IL-10/STAT3/bcl-2 signaling pathway, providing possible new targets for breast tumor therapy.
Literature
1.
go back to reference Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74–80.PubMedCrossRef Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008;8:74–80.PubMedCrossRef
2.
go back to reference Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.PubMedCrossRef Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.PubMedCrossRef
3.
go back to reference Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.PubMedCrossRef Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.PubMedCrossRef
4.
go back to reference Ojalvo LS, King W, Cox D, et al. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol. 2009;174:1048–64.PubMedCentralPubMedCrossRef Ojalvo LS, King W, Cox D, et al. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol. 2009;174:1048–64.PubMedCentralPubMedCrossRef
5.
go back to reference Mukhtar RA, Nseyo O, Campbell MJ, et al. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011;11:91–100.PubMedCrossRef Mukhtar RA, Nseyo O, Campbell MJ, et al. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011;11:91–100.PubMedCrossRef
7.
go back to reference Mantovani A, Sica A, Allavena P, et al. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70:325–30.PubMedCrossRef Mantovani A, Sica A, Allavena P, et al. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70:325–30.PubMedCrossRef
8.
go back to reference McMillin DW, Delmore J, Weisberg E, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010;16:483–9.PubMedCentralPubMedCrossRef McMillin DW, Delmore J, Weisberg E, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010;16:483–9.PubMedCentralPubMedCrossRef
9.
go back to reference Jinushi M, Chiba S, Yoshiyama H, et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA. 2011;108:12425–30.PubMedCentralPubMedCrossRef Jinushi M, Chiba S, Yoshiyama H, et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA. 2011;108:12425–30.PubMedCentralPubMedCrossRef
10.
11.
go back to reference Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.PubMedCrossRef Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.PubMedCrossRef
12.
14.
go back to reference Gritsko T, Williams A, Turkson J, et al. Persistent activation of STAT3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12:11–9.PubMedCrossRef Gritsko T, Williams A, Turkson J, et al. Persistent activation of STAT3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12:11–9.PubMedCrossRef
15.
go back to reference Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–44.PubMed Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–44.PubMed
16.
go back to reference Sun Z, Yao Z, Liu S, et al. An oligonucleotide decoy for STAT3 activates the immune response of macrophages to breast cancer. Immunobiology. 2006;211:199–209.PubMedCrossRef Sun Z, Yao Z, Liu S, et al. An oligonucleotide decoy for STAT3 activates the immune response of macrophages to breast cancer. Immunobiology. 2006;211:199–209.PubMedCrossRef
17.
go back to reference Cohen SBA, Crawley JB, Kahan MC, et al. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 1997;92:1–5.PubMedCentralPubMedCrossRef Cohen SBA, Crawley JB, Kahan MC, et al. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 1997;92:1–5.PubMedCentralPubMedCrossRef
18.
go back to reference Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12:5055–63.PubMedCrossRef Duan Z, Foster R, Bell DA, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006;12:5055–63.PubMedCrossRef
19.
go back to reference Müllauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res/Rev Mutat Res. 2001;488:211–31.CrossRef Müllauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res/Rev Mutat Res. 2001;488:211–31.CrossRef
20.
go back to reference Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315–22.PubMedCrossRef Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315–22.PubMedCrossRef
21.
go back to reference Tjiu JW, Chen JS, Shun CT, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2008;129:1016–25.PubMedCrossRef Tjiu JW, Chen JS, Shun CT, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2008;129:1016–25.PubMedCrossRef
22.
go back to reference Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287:43094–107.PubMedCentralPubMedCrossRef Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287:43094–107.PubMedCentralPubMedCrossRef
23.
go back to reference Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;9:683–765.CrossRef Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;9:683–765.CrossRef
24.
go back to reference Vega MI, Huerta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23:3530–40.PubMedCrossRef Vega MI, Huerta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23:3530–40.PubMedCrossRef
25.
go back to reference Komohara Y, Horlad H, Ohnishi K, et al. Importance of direct macrophage–tumor cell interaction on progression of human glioma. Cancer Sci. 2012;103:2165–72.PubMedCrossRef Komohara Y, Horlad H, Ohnishi K, et al. Importance of direct macrophage–tumor cell interaction on progression of human glioma. Cancer Sci. 2012;103:2165–72.PubMedCrossRef
Metadata
Title
Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway
Authors
Cuixia Yang
Linyan He
Pingqing He
Yiwen Liu
Wenjuan Wang
Yiqing He
Yan Du
Feng Gao
Publication date
01-02-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0352-6

Other articles of this Issue 2/2015

Medical Oncology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine